Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SPRO 
Spero Therapeutics Inc (SPRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: SPRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 0.2% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.52M USD | Price to earnings Ratio 11.12 | 1Y Target Price 5 |
Price to earnings Ratio 11.12 | 1Y Target Price 5 | ||
Volume (30-day avg) 102203 | Beta 0.69 | 52 Weeks Range 0.73 - 1.81 | Updated Date 03/27/2025 |
52 Weeks Range 0.73 - 1.81 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin 3.3% | Operating Margin (TTM) -138.04% |
Management Effectiveness
Return on Assets (TTM) -0.57% | Return on Equity (TTM) 5.89% |
Valuation
Trailing PE 11.12 | Forward PE - | Enterprise Value -23146834 | Price to Sales(TTM) 0.46 |
Enterprise Value -23146834 | Price to Sales(TTM) 0.46 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 54518200 | Shares Floating 40514084 |
Shares Outstanding 54518200 | Shares Floating 40514084 | ||
Percent Insiders 24.47 | Percent Institutions 24.89 |
Analyst Ratings
Rating 3.33 | Target Price 5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Spero Therapeutics Inc
Company Overview
History and Background
Spero Therapeutics, Inc. is a biopharmaceutical company founded in 2013. It focuses on developing novel therapies to treat bacterial infections and unmet medical needs. The company has navigated through clinical trial successes and setbacks, corporate restructuring, and financial challenges.
Core Business Areas
- Anti-Infective Development: Spero Therapeutics is focused on developing novel anti-infective therapies for multi-drug resistant (MDR) bacterial infections. They are pursuing the development of SPR206, a direct acting inhibitor of bacterial DNA gyrase and topoisomerase IV for treating MDR Gram-negative infections.
Leadership and Structure
The leadership team consists of the CEO, CFO, CSO and other key executives, supported by a board of directors. The company has a typical structure for a biopharmaceutical firm, with departments focused on R&D, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- SPR206: SPR206 is a potential treatment for multi-drug resistant Gram-negative infections. It is currently in development, there is no market share or revenue yet. Competitors include companies developing similar antibiotics.
Market Dynamics
Industry Overview
The anti-infective market is driven by the increasing prevalence of antibiotic-resistant bacteria. Factors such as an aging population, increased travel, and overuse of antibiotics contribute to the need for new therapies. The market is competitive, with both large pharmaceutical companies and smaller biotechs developing new drugs.
Positioning
Spero Therapeutics is positioned as a company focused on developing novel therapies for multi-drug resistant infections. Their competitive advantage lies in their unique mechanisms of action and focus on unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for antibiotics is estimated to be billions of dollars annually, addressing various types of infections. Spero Therapeutics' position within this TAM depends on the clinical success and commercialization of their drug candidates. Given the limited number of new antibiotics, SPR206 has potential to capture a sizable market share if it receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for SPR206
- Focus on unmet medical needs in antibiotic resistance
- Experienced management team
- Secured funding
Weaknesses
- Limited financial resources
- Dependence on single product candidate SPR206
- High risk of clinical trial failure
- Regulatory uncertainty
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through in-licensing or acquisition
- Government incentives for antibiotic development
- Potential for Breakthrough Therapy designation
Threats
- Competition from other antibiotic developers
- Changes in regulatory landscape
- Pricing pressures from healthcare payers
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- PFE
- ABBV
Competitive Landscape
Spero Therapeutics faces intense competition from established pharmaceutical companies and other biotech firms. Spero's ability to succeed depends on the differentiated efficacy and safety of its products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on preclinical and clinical development of its pipeline. It has been marked by periods of stock volatility and financings.
Future Projections: Future projections are highly dependent on the success of SPR206. Analyst estimates should be consulted.
Recent Initiatives: Recent initiatives include clinical trials for SPR206, financing, and exploring potential partnerships.
Summary
Spero Therapeutics is a high-risk, high-reward biopharmaceutical company focused on developing novel therapies for multi-drug resistant infections. The success of the company hinges on the clinical development and commercialization of SPR206. Funding and regulatory approvals remain key challenges. The company needs to secure partnerships to expand their product pipeline.
Similar Companies
- AKBA
- CARS
- CTXR
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data may be estimates and should be verified. Financial data should be obtained from official financial statements.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spero Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2017-11-02 | Interim President, Interim CEO, CFO, Chief Business Officer & Treasurer Ms. Esther P. Rajavelu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://sperotherapeutics.com |
Full time employees 46 | Website https://sperotherapeutics.com | ||
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.